Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors

Tista Roy Chaudhuri*, Qingxiang Lin, Ewa K Stachowiak, Spencer R Rosario, Joseph A Spernyak, Wen Wee Ma, Michal K Stachowiak, Michelle K Greene, Gerard P Quinn, Simon S McDade, Martin Clynes, Christopher J Scott, Robert M Straubinger*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose
Paracrine activation of pro-fibrotic hedgehog (HH) signaling in pancreatic ductal adenocarcinoma (PDAC) results in stromal amplification that compromises tumor drug delivery, efficacy, and patient survival. Interdiction of HH-mediated tumor-stroma crosstalk with smoothened (SMO) inhibitors (SHHi) “primes” PDAC patient-derived xenograft (PDX) tumors for increased drug delivery by transiently increasing vascular patency/permeability, and thereby macromolecule delivery. However, patient tumor isolates vary in their responsiveness, and responders show co-induction of epithelial–mesenchymal transition (EMT). We aimed to identify the signal derangements responsible for EMT induction and reverse them and devise approaches to stratify SHHi-responsive tumors noninvasively based on clinically-quantifiable parameters.

Experimental design
Animals underwent diffusion-weighted magnetic resonance (DW-MR) imaging for measurement of intratumor diffusivity. In parallel, tissue-level deposition of nanoparticle probes was quantified as a marker of vascular permeability/perfusion. Transcriptomic and bioinformatic analysis was employed to investigate SHHi-induced gene reprogramming and identify key “nodes” responsible for EMT induction.

Results
Multiple patient tumor isolates responded to short-term SHH inhibitor exposure with increased vascular patency and permeability, with proportionate increases in tumor diffusivity. Nonresponding PDXs did not. SHHi-treated tumors showed elevated FGF drive and distinctly higher nuclear localization of fibroblast growth factor receptor (FGFR1) in EMT-polarized tumor cells. Pan-FGFR inhibitor NVP-BGJ398 (Infigratinib) reversed the SHHi-induced EMT marker expression and nuclear FGFR1 accumulation without compromising the enhanced permeability effect.

Conclusions
This dual-hit strategy of SMO and FGFR inhibition provides a clinically-translatable approach to compromise the profound impermeability of PDAC tumors. Furthermore, clinical deployment of DW-MR imaging could fulfill the essential clinical–translational requirement for patient stratification.

Original languageEnglish
JournalClinical Cancer Research
Early online date20 Feb 2024
DOIs
Publication statusEarly online date - 20 Feb 2024

Fingerprint

Dive into the research topics of 'Dual-hit strategy for therapeutic targeting of pancreatic cancer in patient-derived xenograft tumors'. Together they form a unique fingerprint.

Cite this